AVTE vs. AVBP, IGMS, CDMO, APLT, ATXS, PHAT, ABUS, CMPS, CALT, and LRMR
Should you be buying Aerovate Therapeutics stock or one of its competitors? The main competitors of Aerovate Therapeutics include ArriVent BioPharma (AVBP), IGM Biosciences (IGMS), Avid Bioservices (CDMO), Applied Therapeutics (APLT), Astria Therapeutics (ATXS), Phathom Pharmaceuticals (PHAT), Arbutus Biopharma (ABUS), COMPASS Pathways (CMPS), Calliditas Therapeutics AB (publ) (CALT), and Larimar Therapeutics (LRMR). These companies are all part of the "pharmaceutical preparations" industry.
Aerovate Therapeutics (NASDAQ:AVTE) and ArriVent BioPharma (NASDAQ:AVBP) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their community ranking, analyst recommendations, dividends, institutional ownership, profitability, risk, media sentiment, valuation and earnings.
In the previous week, Aerovate Therapeutics had 2 more articles in the media than ArriVent BioPharma. MarketBeat recorded 14 mentions for Aerovate Therapeutics and 12 mentions for ArriVent BioPharma. ArriVent BioPharma's average media sentiment score of 1.23 beat Aerovate Therapeutics' score of 0.17 indicating that ArriVent BioPharma is being referred to more favorably in the news media.
Aerovate Therapeutics currently has a consensus target price of $47.00, indicating a potential upside of 126.18%. ArriVent BioPharma has a consensus target price of $29.25, indicating a potential upside of 52.58%. Given Aerovate Therapeutics' higher possible upside, analysts plainly believe Aerovate Therapeutics is more favorable than ArriVent BioPharma.
Aerovate Therapeutics received 10 more outperform votes than ArriVent BioPharma when rated by MarketBeat users. However, 100.00% of users gave ArriVent BioPharma an outperform vote while only 65.38% of users gave Aerovate Therapeutics an outperform vote.
ArriVent BioPharma's return on equity of 0.00% beat Aerovate Therapeutics' return on equity.
9.5% of ArriVent BioPharma shares are owned by institutional investors. 19.3% of Aerovate Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
ArriVent BioPharma beats Aerovate Therapeutics on 7 of the 11 factors compared between the two stocks.
Get Aerovate Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AVTE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AVTE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aerovate Therapeutics Competitors List
Related Companies and Tools
